Medicom provides device strategy, product design and development services, specifically focusing on personal connected health drug delivery device solutions for biopharma and specialty pharmaceutical markets.

It offers development and low-volume production services for drug delivery devices, as well as connected health solutions for the high-value rare disease and orphan drug market.

The acquisition is said to expand Phillips-Medisize’s injectable and inhalation device innovation service solutions for biopharma customers.

The service solutions include early device strategy, human factors engineering, product development, clinical production, full scale production and integrated supply chain management.

The combined company will employ around 500 engineers across facilities in the US, Netherlands, Denmark, the UK and China.

Phillips-Medisize chairman and CEO Matt Jennings said: "This transaction is consistent with our strategic focus on serving the rapidly growing diabetes, biologics, specialty pharmaceutical and personalized oncology markets that need these products and reinforces our leading position in drug delivery device solutions."

Medicom CEO Morten Nielsen said: "We are pleased to partner with Phillips-Medisize, a recognized global leader with an impressive track record of delivering a broad and deep set of capabilities to customers."

Phillips-Medisize provides design and manufacturing services for the drug delivery and combination products, consumable diagnostics and medical device, and specialty commercial markets.

Image: Phillips-Medisize has acquired Medicom Innovation Partner. Photo: courtesy of Stuart Miles /